BioCentury
ARTICLE | Company News

Gilead's Yescarta beats estimates

July 26, 2018 1:11 AM UTC

In its 2Q18 earnings released Wednesday, Gilead Sciences Inc. (NASDAQ:GILD) reported better than expected sales of CAR T cell therapy Yescarta axicabtagene ciloleucel. Sales for the drug were $68 million, beating the consensus estimate of $59.1 million and up from $40 million in sales in 1Q18.

On its earnings conference to discuss earnings, EVP and CFO Robin Washington said the company has authorized more than 60 U.S. cancer centers to treat patients with Yescarta, which she said covers about 80% of eligible patients...